Five Bottles, One Answer: Do Opioids Really Relieve Acute Musculoskeletal Pain Better?
It is a Tuesday afternoon and a 34-year-old man is on the gurney after rolling his ankle in a pickup basketball game. The joint is swollen, he cannot bear weight, and the X-ray shows soft tissue swelling without a fracture. He looks up and asks for “something strong.” For most of us, that phrase triggers a familiar internal debate. Do we reach for an opioid, or do we hold the line with a non-opioid combination and risk the perception that we are undertreating?
Underneath that bedside moment sits a genuine clinical question. For acute musculoskeletal pain, does the opioid actually deliver more analgesia, or have we simply inherited the assumption that stronger-sounding means stronger-acting? A 5-arm randomized trial from Bijur and colleagues answers it about as cleanly as emergency medicine ever gets.1
The trial in brief
The investigators ran a randomized clinical trial across 2 urban academic emergency departments, enrolling 600 adults aged 21 to 64 with acute musculoskeletal pain in one or more extremities.1 The cohort was predominantly men and predominantly Latino, and the groups were well matched at baseline on pain scores and diagnoses. Each patient was randomized to one of 5 oral analgesic combinations: 400 mg ibuprofen with 1,000 mg acetaminophen; 800 mg ibuprofen with 1,000 mg acetaminophen; 30 mg codeine with 300 mg acetaminophen; 5 mg hydrocodone with 300 mg acetaminophen; or 5 mg oxycodone with 325 mg acetaminophen.1
The primary outcome was the change in pain on a 0 to 10 numeric rating scale from baseline to 1 hour, with the same comparison and adverse-effect tracking repeated at 2 hours.
What they found
At 1 hour, there was no meaningful difference between the 5 groups. The mean reductions in pain landed at 3.0, 3.0, 3.4, 3.1, and 3.3 points respectively, with a P value of 0.69.1 The two non-opioid arms sat squarely in the middle of the pack. Rescue medication was needed rarely and did not differ by group, and the 2-hour findings told the same story.
Benefit was equal. Harm was not. More patients who received an opioid were nauseated or vomited compared with those who did not, 6.7 percent versus 1.7 percent.1 So the opioid arms bought no additional relief while adding a measurable increase in adverse effects, before we even account for the dependence risk that a 2-hour window cannot capture.
The mechanism that makes this make sense
The result is not a fluke, it is pharmacology. Ibuprofen and acetaminophen relieve pain through different pathways, so combining them produces additive analgesia that competes directly with a low-dose opioid. That is why the humble over-the-counter pairing holds its own against oxycodone in a head-to-head trial.
What about the patient who is still hurting?
A fair objection is the refractory patient, the one who is not better after first-line treatment. A companion trial from the same group speaks to exactly this.2 Opioid-naive patients received ibuprofen first, and those with insufficient relief at 1 hour were randomized to oxycodone with acetaminophen or acetaminophen alone. The opioid combination produced slightly greater relief, a mean difference of 1.1 points on the 0 to 10 scale, but at the cost of substantially more adverse events, 34 percent versus 9 percent.2 So even as a second-line agent, the opioid buys a modest analgesic gain against a steep side-effect trade.
How Should This Modify Your Practice?
For acute musculoskeletal pain, the default should be a non-opioid combination of ibuprofen plus acetaminophen, dosed to effect. The best available head-to-head data say you are not sacrificing analgesia by starting there, and you are avoiding a measurable burden of nausea and vomiting along with the dependence risk that lives outside the trial window.
Reserve opioids for the genuine outliers: the patient with a contraindication to nonsteroidals, the truly refractory case, the specific clinical situation that demands it. When you do reach for one, do it as a deliberate, consented decision rather than a reflex, and set expectations that the marginal analgesic gain comes with a real side-effect cost. Framing the non-opioid combination as the evidence-based first move, not the budget option, also helps recalibrate the patient who equated “strong” with “better.”
None of this is anti-opioid absolutism. It is simply practicing at the top of the evidence. Same relief, fewer harms, for the large majority of patients who walk in with a sprain, a strain, or a rolled ankle.
Dr Adrian Cois, MD
Assistant Professor, Emergency Medicine
@dr_cois
Disclosure: No financial relationships relevant to this content. No affiliate links. This post is educational and does not constitute medical advice or establish a physician–patient relationship.
Related Reading
● Overheard Journal Club Episode 1: balanced crystalloids versus saline (SALT-ED).
● ACEP and CDC guidance on opioid prescribing for acute pain in the emergency department (see references).
References
1. Bijur PE, Friedman BW, Irizarry E, Chang AK, Gallagher EJ. A Randomized Trial Comparing the Efficacy of Five Oral Analgesics for Treatment of Acute Musculoskeletal Extremity Pain in the Emergency Department. Ann Emerg Med. 2021;77(3):345-356. doi:10.1016/j.annemergmed.2020.10.004
2. Friedman BW, Irizarry E, Feliciano C, et al. A randomized controlled trial of oxycodone/acetaminophen versus acetaminophen alone for emergency department patients with musculoskeletal pain refractory to ibuprofen. Acad Emerg Med. 2021;28(8):859-865. doi:10.1111/acem.14231
